%0 Journal Article
%T Clinical potential of serum prostaglandin A2 as a novel diagnostic biomarker for hepatocellular cancer.
%A Liu L
%A Li YN
%A Zhang A
%A Yin Y
%A Yue Z
%A Pei L
%A Xia CS
%A Wang D
%A Jia M
%A Wang H
%A Cao LL
%J Clin Chim Acta
%V 561
%N 0
%D 2024 Jul 15
%M 38879063
%F 6.314
%R 10.1016/j.cca.2024.119814
%X <B>BACKGROUND: </B>Hepatocellular cancer (HCC) is one of the most harmful tumors to human health. Currently, there is still a lack of highly sensitive and specific HCC biomarkers in clinical practice. In this study, we aimed to explore the diagnostic performance of prostaglandin A2 (PGA2) for the early detection of HCC.<BR><B>METHODS: </B>Untargeted metabolomic analyses on normal control (NC) and HCC participants in the discovery cohort were performed, and PGA2 was identified to be dysregulated in HCC. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for detecting serum PGA2 was established and applied to validate the dysregulation of PGA2 in another independent validation cohort. Receiver operating characteristic (ROC), decision curve analysis (DCA) and some other statistical analyses were performed to evaluate the diagnostic performance of PGA2 for HCC.<BR><B>RESULTS: </B>At first, PGA2 was found to be dysregulated in HCC in untargeted metabolomic analyses. Then a precise quantitative LC-MS/MS method for PGA2 has been established and has passed rigorous method validation. Targeted PGA2 analyses confirmed that serum PGA2 was decreased in HCC compared to normal-risk NC and high-risk cirrhosis group. Subsequently, PGA2 was identified as a novel biomarker for the diagnosis of HCC, with an area under the ROC curve (AUC) of 0.911 for differentiating HCC from the combined NC + cirrhosis groups. In addition, PGA2 exhibited high performance for differentiating small-size (AUC = 0.924), early-stage (AUC = 0.917) and AFP (-) HCC (AUC = 0.909) from the control groups. The combination of PGA2 and AFP might be useful in the surveillance of risk population for HCC and early diagnosis of HCC.<BR><B>CONCLUSIONS: </B>This study establishes that PGA2 might be a novel diagnostic biomarker for HCC.